Zykadia Cap passes first wall of insurance benefit registration
A Novartis’s lung cancer therapy, Zykadia Cap(ceritinib) received a ‘insurance benefit adequacy’ evaluation as applied by a special case to be exempted in economic evaluation. It, thus, became the 5th drug which passed the insurance benefit wall through the so-called ‘economic evaluation exemptio...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
